Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform
Pancreatic cancer is a rapidly developing cancer with a poor prognosis. The FOLFIRINOX protocol has become the standard medical treatment for this pathology. However, FOLFIRINOX is the cause of severe toxicities dominated by leuko-neutropenia, thrombocytopenia, diarrhea, nausea-vomiting, anorexia, asthenia, weight loss and peripheral sensory neuropathy. Therefore, its indication is limited to patients in good general condition . In practice, it is interrupted upon the occurrence of grade 3-4 toxicities, hematological and / or clinical. A monitoring would allow early identification of the deterioration or improvement in the health of these fragile patients while they are not hospitalized, and trigger proactive interventions. It is in this context that the study presented here proposes to monitor patients with advanced pancreatic cancer during the month following the 1st cycle of FOLFIRINOX in conventional administration using the platform. PiCADo mobile.
Start: June 2020